Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Appointed director
Notes underwriting agrmnt
Ayala Pharmaceuticals, Inc. (ADXS) Create: Alert

All | News | Filings
Date FiledTypeDescription
03/12/2018 BW Advaxis Reports Fiscal 2018 First Quarter Financial Results and Announces Clinical Hold in Axalimogene Filolisbac Phase 1/2 Combination Study with AstraZeneca's IMFINZI® (Durvalumab)
03/09/2018 BW Advaxis to Host Business Update and First Quarter 2018 Financial Results Conference Call on March 12, 2018
12/20/2017 BW Advaxis Reports Fiscal Year 2017 Financial Results and Provides a Business Update
12/14/2017 BW Advaxis to Host Business Update and Fiscal Year End 2017 Financial Results Conference Call on December 21, 2017
09/21/2017 BW Advaxis to Webcast Company Overview at the Cantor Fitzgerald Global Healthcare Conference
09/11/2017 BW Advaxis Reports Business Update and Third Quarter 2017 Results
06/09/2017 BW Advaxis to Webcast Investor & Analyst Day 2017
06/08/2017 BW Update: Webcast of Advaxis Presentation at Jefferies 2017 Global Healthcare Conference Now Available
08/11/2011 BW Advaxis Completes Pre-IND Meeting for ADXS-PSA
07/20/2011 BW Dr. Ashok Amin Joins Advaxis as Vice President of Research and Development
07/11/2011 BW Advaxis Completes Enrollment of Low Dose Cohort in CIN Study
06/30/2011 BW Advaxis Granted Pre-IND Meeting with the FDA for Advaxis-PSA Prostate Immunotherapy
06/29/2011 BW Chris L. French Joins Advaxis as Executive Director of Medical Affairs
04/18/2011 BW Advaxis Lead Drug ADXS11-001 Well-Tolerated in 72 Patients, to Date
04/14/2011 BW Advaxis Announces Collaboration with Wistar Institute
04/12/2011 BW Equity Research Initiated on Advaxis by Zacks Equity Research
04/05/2011 BW Advaxis Receives FINRA Approval to Relist on OTC Bulletin Board
03/04/2011 BW Advaxis Chairman/CEO Addresses Company Stock Trading on OTCQB
02/15/2011 BW Advaxis Included in the Mentor Capital Cancer Immunotherapy Index
12/14/2010 BW Advaxis 2010 Science Update Conference Call
12/08/2010 BW Advaxis to Present at the LD Micro Conference
11/24/2010 BW Advaxis India Cervix Cancer Trial Begins Dosing
11/08/2010 BW Advaxis Enters into Collaboration with the University of British Columbia
11/01/2010 BW Advaxis to Present at the Fifth Annual Singular Research “Best of the Uncovereds” Conference
10/29/2010 BW Advaxis Signs CRADA with Vaccine Branch of NCI
10/21/2010 BW Advaxis Completes Recruitment of First 11 Patients in US Cervical Dysplasia Study
10/14/2010 BW Advaxis to Present at the 6th Annual Fall Growth Stock Conference Hosted by Security Research Associates, Inc.
10/12/2010 BW Dr. Robert Petit Joins Advaxis as V.P. of Clinical Operations
10/01/2010 BW Advaxis to Present at the 9th Annual BIO Investor Forum Conference
09/24/2010 BW Advaxis Chairman and CEO Issues Statement to Shareholders
09/22/2010 BW India Approves Advaxis Trial in Cervix Cancer
09/16/2010 BW Advaxis Chairman/CEO Thomas A. Moore Outlined Strategic Plan at the 2010 Rodman & Renshaw Global Healthcare Conference
09/10/2010 BW Advaxis Publishes Research on New Her2 Vaccine
09/09/2010 BW U.S. Patent and Trademark Office Issues Patent for Live Listeria HER2/neu Immunotherapy
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy